Imagine hearing the words: your child has cancer.
Then hearing the second sentence:
The treatment costs ₹35–50 lakh. Upfront.
For most Indian families, that's where hope quietly dies.
Not because the medicine doesn't exist.
But because the money doesn't.
Bengaluru-based Immuneel Therapeutics — co-founded by biotech icon Kiran Mazumdar-Shaw — just did something rare in Indian healthcare.
They partnered with Mumbai NBFC Arogya Finance to offer a ₹25 lakh zero-cost EMI for cancer patients.
No interest. Just monthly instalments. Up to 12 months.
This isn't a discount coupon. It's a lifeline.
Immuneel makes Qartemi — India's first homegrown CAR T-cell therapy for adult non-Hodgkin lymphoma.
A therapy that in the US costs upwards of ₹3–4 crore.
In India? Around ₹35–50 lakh. Roughly one-tenth the global price.
Still life-changing money for most families.
Still a wall.
👉 The zero-cost EMI is designed to break that wall.
The flow is refreshingly clean:
Every year, over 1.2 lakh Indians are diagnosed with blood cancers like leukaemia and lymphoma.
Most never even get the option of advanced cellular therapy.
Indian healthcare has spent decades obsessing over one word: affordability.
Cheaper drugs. Cheaper surgeries. Cheaper diagnostics.
But cutting-edge therapies — CAR-T, gene editing, precision oncology — don't get cheap overnight.
So the next frontier isn't just lower prices.
It's smarter financing.
EMIs for cancer. Interest-free loans for gene therapy. Credit built around clinical eligibility, not just credit scores.
This is a new grammar for Indian medicine.
Innovation in healthcare only matters when a patient can actually reach it.
A molecule locked behind a ₹40 lakh wall helps no one.
Immuneel just proved something quietly powerful:
Sometimes the breakthrough isn't in the lab.
It's in the payment plan.
That's all for now!
